Am J Blood Res 2011;1(2):204-214
Original Article
C-MOPP: The forgotten regimen plus Rituximab for untreated and relapsed
follicular lymphoma
Mark J. Fesler, Medhat Osman, James Glauber, Paul J. Petruska
Department of Internal Medicine, Division of Hematology and Medical Oncology, Saint Louis University; Division of Nuclear
Medicine Medical Director, Saint Louis University; Missouri Hematology and Oncology; Department of Internal Medicine,
Division of Hematology and Medical Oncology, Saint Louis University, MO, USA.
Received September 1, 2011; accepted September 19, 2011; Epub September 22, 2011; published September 30, 2011
Abstract: C-MOPP is a chemotherapy regimen for the treatment of Non-Hodgkin lymphoma (NHL). Because rituximab
improves results in B-cell NHL, we added rituximab to C-MOPP, giving it the term C-MOPP-R. We retrospectively report the
results of C-MOPP-R treatment for follicular lymphoma at Saint Louis University Cancer Center from 2000-2009. Treatment
response was assessed with fusion PET/CT using International Harmonization Project Criteria and toxicity using National
Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. Thirty-seven patients with follicular lymphoma
were treated at our institution with C-MOPP-R. The complete response rate was ninety-four percent and sixty-eight percent in
untreated and relapsed patients, respectively. The median progression-free and overall survivals were not reached with
median observation time of 34 months. Development of peripheral neuropathy required truncation of planned vincristine
dosing in nearly half of patients. We believe that C-MOPP-R results in excellent response rates, progression-free, and overall
survival for untreated and relapsed follicular lymphoma and capped vincristine dosing is essential to optimize safety.
(AJBR1109001).
Keywords: Lymphoma, Non-Hodgkin, Positron Emission Tomography, Antibodies, Monoclonal, antineoplastic agents
Full Text PDF
Address all correspondence to:
Mark J. Fesler, MD
3655 Vista Avenue
Saint Louis, MO 63110
Tel: 314-577-8854, Fax: 314-773-1167
Original Article
C-MOPP: The forgotten regimen plus Rituximab for untreated and relapsed
follicular lymphoma
Mark J. Fesler, Medhat Osman, James Glauber, Paul J. Petruska
Department of Internal Medicine, Division of Hematology and Medical Oncology, Saint Louis University; Division of Nuclear
Medicine Medical Director, Saint Louis University; Missouri Hematology and Oncology; Department of Internal Medicine,
Division of Hematology and Medical Oncology, Saint Louis University, MO, USA.
Received September 1, 2011; accepted September 19, 2011; Epub September 22, 2011; published September 30, 2011
Abstract: C-MOPP is a chemotherapy regimen for the treatment of Non-Hodgkin lymphoma (NHL). Because rituximab
improves results in B-cell NHL, we added rituximab to C-MOPP, giving it the term C-MOPP-R. We retrospectively report the
results of C-MOPP-R treatment for follicular lymphoma at Saint Louis University Cancer Center from 2000-2009. Treatment
response was assessed with fusion PET/CT using International Harmonization Project Criteria and toxicity using National
Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. Thirty-seven patients with follicular lymphoma
were treated at our institution with C-MOPP-R. The complete response rate was ninety-four percent and sixty-eight percent in
untreated and relapsed patients, respectively. The median progression-free and overall survivals were not reached with
median observation time of 34 months. Development of peripheral neuropathy required truncation of planned vincristine
dosing in nearly half of patients. We believe that C-MOPP-R results in excellent response rates, progression-free, and overall
survival for untreated and relapsed follicular lymphoma and capped vincristine dosing is essential to optimize safety.
(AJBR1109001).
Keywords: Lymphoma, Non-Hodgkin, Positron Emission Tomography, Antibodies, Monoclonal, antineoplastic agents
Full Text PDF
Address all correspondence to:
Mark J. Fesler, MD
3655 Vista Avenue
Saint Louis, MO 63110
Tel: 314-577-8854, Fax: 314-773-1167
| AJBR Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
 |  |  |  |  |  |  |